Antifungal Pipeline

Frontiers in Cellular and Infection Microbiology

Todd Patrick McCarty¹  Peter G. Pappas² 

[1] Department of Medicine, Birmingham Veterans Affairs (VA) Medical Center, Birmingham, AL, United States;Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States;

关键词: antifungal;    mycology;    Candida;    aspergillosis;    fungal infections;    antimicrobials;   

DOI  :  10.3389/fcimb.2021.732223

来源: DOAJ

【 摘 要 】

In many ways, fungal diseases are forgotten or neglected. Given the significantly lower frequency compared to similar bacterial etiologies across the spectrum of infectious syndromes, it makes sense that anti-bacterial agents have seen the bulk of development in recent decades. The vast majority of new antifungal medications approved for use in the past 10 years have been new versions in the same class as existing agents. Clinical mycology is crying out for new mechanisms of action in the setting of rising resistance and emergence of new organisms. Fortunately, this trend appears to be reversing. There are numerous agents in advanced stages of development offering novel dosing regimens and mechanisms of action to combat these threats. Herein we review seven antifungal agents that we hope to see come to market in the coming years to aid physicians in the treatment of mucocutaneous and invasive fungal infections.

【 授权许可】

Unknown